Lijuan Zou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lijuan Zou has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ang Qu
Department of Radiation Oncology, Peking University Third Hospital, Beijing, China
1 shared publication - Chenghui Song
Maternal and Child Health Hospital of Shahekou District, Dalian, China
1 shared publication - Fuquan Zhang
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication - Fuxiu Ye
Department of Radiation Oncology, The Second Hospital of Dalian Medical University, China
1 shared publication - Haichen Zhang
Department of Radiation Oncology, The Second Hospital of Dalian Medical University, China
1 shared publication - Hongwei Lei
Department of Radiation Oncology, The Second Hospital of Dalian Medical University, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (3)
Nimotuzumab plus concurrent chemoradiotherapy sequential maintenance treatment for locally advanced cervical squamous cell carcinoma (NOTABLE-306): a multicenter, prospective, randomized, double-blind, placebo-controlled trial
Wei S, et al. J Gynecol Oncol. 2025 Dec;37:e46. https://doi.org/10.3802/jgo.2026.37.e46
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (3)
Open AccessNimotuzumab plus concurrent chemoradiotherapy sequential maintenance treatment for locally advanced cervical squamous cell carcinoma (NOTABLE-306): a multicenter, prospective, randomized, double-blind, placebo-controlled trial
Wei S, et al. J Gynecol Oncol. 2025 Dec;37:e46. https://doi.org/10.3802/jgo.2026.37.e46
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35 (6)
Prognostic values of tumor size and location in early stage endometrial cancer patients who received radiotherapy
Jiao S, et al. J Gynecol Oncol. 2024 Apr;35:e84. https://doi.org/10.3802/jgo.2024.35.e84
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35 (6)
Open AccessPrognostic values of tumor size and location in early stage endometrial cancer patients who received radiotherapy
Jiao S, et al. J Gynecol Oncol. 2024 Apr;35:e84. https://doi.org/10.3802/jgo.2024.35.e84
- Open Access
- 11 June 2021
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 30 (7) , 727-736
Baicalein modulates the radiosensitivity of cervical cancer cells in vitro via miR-183 and the JAK2/STAT3 signaling pathway
Increasing radiosensitivity of cancer cells can enhance the efficacy of cervical cancer treatment. This study evaluated the potential roles and mechanism of baicalein in regulating the radiosensitivity of cervical cancer cells in vitro. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to assess miR-183 expression in End1/E6E7 cells, Hela cells and Hela cells irradiated with X-ray (0 Gy, 1 Gy, 3 Gy, 5 Gy, and 10 Gy). Cell Counting Kit-8 (CCK-8) method measured cell viability of Hela cells after miR-183 regulation, baicalein or RO8191 treatment. Apoptosis rates were detected using flow cytometry. Thereafter, expression of Bcl-2, Bax and caspase-3 RNA was also detected through RT-qPCR. Protein concentrations of E-cadherin, N-cadherin, Vimentin in epithelial-mesenchymal transition (EMT), phospho-JAK2/STAT3, and total Janus kinase 2/signal transducer and activator of transcription 3 STAT3 (JAK2/STAT3) were examined using enzyme-linked immunosorbent assay (ELISA) methods. RO8191, a JAK2/STAT3 activator, was used to activate the JAK2/STAT3 signaling pathway. The miR-183 expression was significantly lower in Hela cells compared to End1/E6E7 cells. Following upregulation of miR-183 in Hela cells, cell viability was inhibited while apoptosis was promoted. Moreover, EMT was inhibited after miR-183 over-expression. X-ray treatment markedly reduced the cell survival rate and increased miR-183 RNA expression. Baicalein treatment severely reduced the cell viability of 10-Gy X-ray-irradiated Hela cells, partially reversing the effect of miR-183, and also increased apoptosis and prevented EMT in irradiated cells. Y1007/8 in JAK2 and tyrosine (Tyr) residue 705 of STAT3 were phosphorylated, resulting in high expression of JAK2/STAT3, which was decreased by irradiation and baicalein treatment. RO8191 activated JAK2/STAT3 signaling, promoted cell viability and EMT, and inhibited cell apoptosis, while baicalein partly reversed the functions of RO8191. Baicalein inhibited cell viability and EMT, and induced cell apoptosis of Hela cells, through upregulating miR-183 via inactivation of the JAK2/STAT3 signaling pathway.
- 11 June 2021
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 30 (7) , 727-736
Open AccessBaicalein modulates the radiosensitivity of cervical cancer cells in vitro via miR-183 and the JAK2/STAT3 signaling pathway
Increasing radiosensitivity of cancer cells can enhance the efficacy of cervical cancer treatment. This study evaluated the potential roles and mechanism of baicalein in regulating the radiosensitivity of cervical cancer cells in vitro. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to assess miR-183 expression in End1/E6E7 cells, Hela cells and Hela cells irradiated with X-ray (0 Gy, 1 Gy, 3 Gy, 5 Gy, and 10 Gy). Cell Counting Kit-8 (CCK-8) method measured cell viability of Hela cells after miR-183 regulation, baicalein or RO8191 treatment. Apoptosis rates were detected using flow cytometry. Thereafter, expression of Bcl-2, Bax and caspase-3 RNA was also detected through RT-qPCR. Protein concentrations of E-cadherin, N-cadherin, Vimentin in epithelial-mesenchymal transition (EMT), phospho-JAK2/STAT3, and total Janus kinase 2/signal transducer and activator of transcription 3 STAT3 (JAK2/STAT3) were examined using enzyme-linked immunosorbent assay (ELISA) methods. RO8191, a JAK2/STAT3 activator, was used to activate the JAK2/STAT3 signaling pathway. The miR-183 expression was significantly lower in Hela cells compared to End1/E6E7 cells. Following upregulation of miR-183 in Hela cells, cell viability was inhibited while apoptosis was promoted. Moreover, EMT was inhibited after miR-183 over-expression. X-ray treatment markedly reduced the cell survival rate and increased miR-183 RNA expression. Baicalein treatment severely reduced the cell viability of 10-Gy X-ray-irradiated Hela cells, partially reversing the effect of miR-183, and also increased apoptosis and prevented EMT in irradiated cells. Y1007/8 in JAK2 and tyrosine (Tyr) residue 705 of STAT3 were phosphorylated, resulting in high expression of JAK2/STAT3, which was decreased by irradiation and baicalein treatment. RO8191 activated JAK2/STAT3 signaling, promoted cell viability and EMT, and inhibited cell apoptosis, while baicalein partly reversed the functions of RO8191. Baicalein inhibited cell viability and EMT, and induced cell apoptosis of Hela cells, through upregulating miR-183 via inactivation of the JAK2/STAT3 signaling pathway.